MALAT1 and neoplasm: These observations highlight the important role of MALAT1/miR‐140‐5p/Aurora‐A axis in sorafenib resistance and reinforce the notion that MALAT1 can be a prominent therapeutic target to overcome sorafenib resistance in HCC tumours.87